Home > Gastroenterology > UEGW 2020 > UEGW Round-Up Articles > Risk factors for severe COVID-19 among IBD patients

Risk factors for severe COVID-19 among IBD patients

Presented By
Dr Ryan C. Ungaro, Icahn School of Medicine at Mount Sinai, USA
Conference
UEGW 2020
Trial
SECURE-IBD
  Increasing age, comorbidities, and corticosteroids are associated with severe COVID-19 among IBD patients, according to a large, international registry created to monitor outcomes of IBD patients with confirmed COVID-19, called SECURE-IBD [1]. Notably, use of TNF antagonists does not appear to be associated with severe COVID-19. The impact of COVID-19 on patients with inflammatory bowel disease (IBD) is not well characterised. The SECURE-IBD survey catalogued the clinical course of COVID-19 among IBD patients and evaluated the association between demographics, clinical characteristics, and immunosuppressant treatments on COVID-19 outcomes. Reported were 959 COVID-19 cases from 40 countries (median age 43 years, 52% men). Of those, 86 patients (9%) had severe COVID-19, 320 (33%) were hospitalised, and 37 patients died (3.9% case fatality rate). Age-standardised mortality ratios for IBD patients were: 0 relative to ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on